0
Login

NovoCure Limited Ordinary Shares

NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commerc...

instructor-image Bradford Hall

0

... En
... Certificate Company
... 0 Investors
... 00h 00m
NVCR logo
NovoCure Limited Ordinary Shares
NVCR SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · Market Cap: $2B
$15.51 ▲ +1.04%
+$0.16 today · as of 12 Sep 2026
49 S.I.F.T
S.I.F.T.™ Analysis
Red
Login to Issue Journal
Caution – significant pillar weakness detected.
Last updated: 12 Sep 2026 · Confidence: 55%
Pillar Breakdown
🛡 Safety 35
Balance sheet or moat concerns are weighing on the score.
💰 Income 35
High cyclicality and lack of recurring revenue are limiting stability.
📊 Fundamentals 35
Strong growth but valuation is elevated.
⏱ Time 65
Shorter track record or weaker tailwinds.
🧠 Munger Reality Filter AVOID

Proprietary TTFields technology offers differentiation but weak financials and low pillar scores undermine any sustainable moat.

Strengths: Unique oncology platform with multiple pipeline candidates, Majority revenue from established US market, Moderate time_in_market score of 65
Risks: Negative ROE of -18.68 signaling ongoing losses, Debt-to-CFO ratio of 999 indicating severe leverage issues, Zero warchest, dividend, and low safety/fundamentals scores
📈 Price History

Business Overview

NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
Key Metrics
ROE (10yr)
-18.7%
Debt / CFO
N/A
Div. Yield
0.00%
FCF Growth
0.0%

FAQ

Financial Details

Recent Quarters
Quarter Revenue Gross Profit EPS
No quarterly data available.
Segment Breakdown
Data Center 56%
Client 28%
Gaming 9%
Embedded 7%

Management

Leadership Summary
  • - Experienced founding team with deep expertise in oncology medical devices
  • - Strong emphasis on clinical evidence and regulatory approvals for TTFields technology
  • - Focused on international expansion and new indication development
  • - Transparent communication with investors on growth metrics and pipeline
Track Record

Successfully commercialized Optune device with multiple FDA approvals, achieved consistent revenue growth from under $100M to over $500M annually, and expanded into multiple cancer indications despite initial skepticism.

Recent Commentary

“In latest earnings, leadership highlighted European reimbursement progress and ongoing Phase 3 trials, while acknowledging slower US adoption rates and committing to cost discipline.”

Analyst Reviews & Risks

Wall Street Consensus
4.6
out of 5 (Strong Buy)
Average Target: $485.00
Key Investment Risks
  • Negative ROE of -18.68 signaling ongoing losses
  • Debt-to-CFO ratio of 999 indicating severe leverage issues
  • Zero warchest, dividend, and low safety/fundamentals scores
Ownership & Sentiment

Institutional Ownership: N/A%

Short Interest: N/A%

AI Investment Thesis
  • NovoCure's Tumor Treating Fields (TTFields) represent a novel, non-invasive oncology modality with demonstrated survival benefits in glioblastoma and expanding indications in mesothelioma and other solid tumors.
  • Large addressable market driven by rising cancer incidence and demand for therapies with favorable safety profiles compared to traditional chemotherapy.
  • Robust intellectual property portfolio and regulatory exclusivities provide competitive moat through at least the mid-2030s.
  • Pipeline expansion via ongoing Phase 3 trials in lung, ovarian, and pancreatic cancers offers multi-year catalysts for label growth.
  • Improving commercial execution with increasing reimbursement coverage and physician adoption supports path to profitability.
Key Catalysts & Risks
Catalysts
  • Top-line data from LUNAR Phase 3 trial in non-small cell lung cancer (expected 2024)
  • Potential FDA approval and launch in new indications
  • Positive Medicare coverage expansions or new payer contracts
  • Strategic partnerships or licensing deals for international markets
Risks
  • Clinical trial failures or delays in key indications
  • Reimbursement or pricing pressure in major markets
  • Competition from established oncology modalities or new entrants
  • Ongoing cash burn and dilution risk until sustained profitability
Peer Comparison
Company P/E Rev Growth Gross Margin ROE Debt/Equity
NVDA N/A N/A% N/A% 60.22% 0.68
INTC N/A N/A% N/A% -5.53% 6.65
AVGO N/A N/A% N/A% 16.36% 2.72
AMD N/A N/A% N/A% 7.62% 1.83
  • ...

    Investors

     0

  • Ticker

     NVCR
  • ...

    Sector

     SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

  • Current Price

     $15.51

  • S.I.F.T. Score

     49
Login to Add Portfolio